Theriva Biologics (FRA:SFY) Total Liabilities : €13.44 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Theriva Biologics Total Liabilities?

Theriva Biologics's Total Liabilities for the quarter that ended in Mar. 2024 was €13.44 Mil.

Theriva Biologics's quarterly Total Liabilities declined from Sep. 2023 (€16.55 Mil) to Dec. 2023 (€14.23 Mil) and declined from Dec. 2023 (€14.23 Mil) to Mar. 2024 (€13.44 Mil).

Theriva Biologics's annual Total Liabilities increased from Dec. 2021 (€4.39 Mil) to Dec. 2022 (€16.33 Mil) but then declined from Dec. 2022 (€16.33 Mil) to Dec. 2023 (€14.23 Mil).

Theriva Biologics Total Liabilities Historical Data

The historical data trend for Theriva Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Total Liabilities Chart

Theriva Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

5.17

2.59

4.39

16.33

14.23

Theriva Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															16.16	16.33	16.55	14.23	13.44

Theriva Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Theriva Biologics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.179	+	(1.471	+	5.753
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.831	+	0)
	=	14.23

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	50.636	-	36.402
	=	14.23

Theriva Biologics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.528	+	(1.341	+	5.958
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.611	+	0)
	=	13.44

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	44.832	-	31.393
	=	13.44

Theriva Biologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Theriva Biologics (FRA:SFY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

TOVX:USA

Address

9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website

https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor • 07-25-2022

SoFi Releases SoFi Gig Economy ETF (GIGE) and SoFi 50 ETF (SFYF)

By PRNewswire PRNewswire • 05-08-2019